Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414899 | 0.93 | TRPV1 (0.43) | TRPV1ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL4415691 | 0.89 | TRPV1 (0.52) | TRPV1MCHR1 | |
| SCHEMBL4423657 | 0.87 | MAPT (0.42) | TRPV1ADRA1A | |
| SCHEMBL4425779 | 0.87 | TRPV1 (0.48) | TRPV1ADRA1AHDAC1L3MBTL3L3MBTL1 | |
| SCHEMBL4419310 | 0.86 | TRPV1 (0.42) | TRPV1 | |
| SCHEMBL4418100 | 0.86 | MCHR1 (0.46) | TRPV1L3MBTL3KCNH2MCHR1HRH3 | |
| SCHEMBL4425066 | 0.85 | TRPV1 (0.45) | TRPV1L3MBTL1KCNH2MCHR1 | |
| SCHEMBL4415708 | 0.85 | SMN1; SMN2 (0.51) | TRPV1L3MBTL1 | |
| SCHEMBL4414870 | 0.84 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL4417791 | 0.84 | MAPT (0.46) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1680124-A4 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2009-05-13 | — | — | EP | claimed |
| JP-2007508374-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1680124-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005037216-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | TRPV1 1359/4885ADRA1A 618/4885HDAC1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.